Drugmakers kick off 2021 with 500 US price hikes
Skip to main content
  • Home
  • Economy
  • Stocks
  • Analysis
  • World+Biz
  • Sports
  • Splash
  • Features
  • Videos
  • Long Read
  • Games
  • Epaper
  • More
    • COVID-19
    • Bangladesh
    • Infograph
    • Interviews
    • Offbeat
    • Thoughts
    • Podcast
    • Quiz
    • Tech
    • Subscribe
    • Archive
    • Trial By Trivia
    • Magazine
    • Supplement
  • বাংলা
The Business Standard
SATURDAY, MAY 21, 2022
SATURDAY, MAY 21, 2022
  • Home
  • Economy
  • Stocks
  • Analysis
  • World+Biz
  • Sports
  • Splash
  • Features
  • Videos
  • Long Read
  • Games
  • Epaper
  • More
    • COVID-19
    • Bangladesh
    • Infograph
    • Interviews
    • Offbeat
    • Thoughts
    • Podcast
    • Quiz
    • Tech
    • Subscribe
    • Archive
    • Trial By Trivia
    • Magazine
    • Supplement
  • বাংলা
Drugmakers kick off 2021 with 500 US price hikes

Global Economy

Reuters
05 January, 2021, 08:45 pm
Last modified: 05 January, 2021, 08:52 pm

Related News

  • North Korea's Dr Fauci? Health official emerges as face of Covid campaign
  • Shanghai detects new infections after five days of 'zero Covid'
  • North Korea hails 'good results' on Covid as fever cases pass 2 million
  • China relaxes some Covid test rules for US, other travellers
  • New York Times pauses return to office for workers

Drugmakers kick off 2021 with 500 US price hikes

The hikes come as drugmakers are reeling from effects of the Covid-19 pandemic, which has reduced doctor visits and demand for some drugs

Reuters
05 January, 2021, 08:45 pm
Last modified: 05 January, 2021, 08:52 pm
FILE PHOTO: Customers wait in the pharmacy department at a Target store in the Brooklyn borough of New York June 15, 2015. REUTERS/Brendan McDermid/File Photo
FILE PHOTO: Customers wait in the pharmacy department at a Target store in the Brooklyn borough of New York June 15, 2015. REUTERS/Brendan McDermid/File Photo

Drugmakers including Abbvie Inc and Bristol Myers Squibb raised US list prices on more than 500 drugs to kick off 2021, according to an analysis by health care research firm 46brooklyn.

The hikes come as drugmakers are reeling from effects of the Covid-19 pandemic, which has reduced doctor visits and demand for some drugs. They are also fighting new drug price-cutting rules from the Trump administration, which would reduce the industry's profitability.

They include more than 300 price increases from companies like Pfizer and GlaxoSmithKline reported by Reuters late last week.

Nearly all the increases were below 10%, and the median hike was 4.8%, down slightly from last year, 46brooklyn said. The firm's analysis is based on data from Elsevier's Gold Standard Drug Database.

Abbvie raised prices on around 40 drugs including a 7.4% hike on rheumatoid arthritis treatment Humira, the world's top-selling drug. Revenue from Humira is expected to top $20 billion next year.

Bristol Myers hiked prices on around a dozen drugs, including cancer drugs Revlimid and Opdivo by 4.5 percent and 1.5 percent, respectively. It hiked the price of blood thinner Eliquis by 6 percent.

It said in a statement that it only raised prices on drugs with ongoing clinical research. It expects net prices, which include rebates and other discounts, to fall this year.

Drug price increases have slowed substantially since 2015, both in terms of the size of the hikes and the number of drugs affected.

However, 46brooklyn said its analysis of Medicaid data shows the average cost per branded drug is still ticking up.

"Over time, we end up cycling out cheaper brands designed to treat large populations, and replacing them with expensive brands designed to treat smaller populations," wrote Eric Pachman, president of 46brooklyn. "With price increases losing their impact, launch prices will be the primary driver of US drug list price inflation.

Top News / World+Biz

Drug Prices / COVID-19

Comments

While most comments will be posted if they are on-topic and not abusive, moderation decisions are subjective. Published comments are readers’ own views and The Business Standard does not endorse any of the readers’ comments.

Top Stories

  • Infographic: TBS
    Tough conditions get in way of Indian wheat import
  • Zahid Hussain/TBS Sketch
    Our problematic macroeconomic duo
  • US growth seen outpacing China’s for first time since 1976
    US growth seen outpacing China’s for first time since 1976

MOST VIEWED

  • US growth seen outpacing China’s for first time since 1976
    US growth seen outpacing China’s for first time since 1976
  • A worker displays grains of wheat at a mill in Beirut, Lebanon, March 1, 2022. REUTERS/Mohamed Azakir/File Photo
    Russia can offer 25 mln tonnes of grain for export starting on 1 Aug: UN envoy
  • A model of the natural gas pipeline is seen in front of displayed German and Russian flag colours in this illustration taken April 26, 2022. REUTERS/Dado Ruvic/Illustration
    Fearing Russian cutoff, German industry braces for gas rations race
  • A man walks past a Nationwide Building Society in London, Britain, May 22, 2019. REUTERS/Hannah McKay
    Britain's Nationwide annual profit nearly doubles
  • Protestors stand on a water cannon vehicle as they shout slogans during a protest organised by students near the President's House, amid the country's economic crisis, in Colombo, Sri Lanka, May 19, 2022. REUTERS/Adnan Abidi/File Photo
    'We are going to die': Sri Lanka warns of food shortages
  • A woman walks past the International Monetary Fund (IMF) logo at its headquarters in Washington, US, 10 May 12018. Photo: REUTERS
    IMF urges Asia to be mindful of spillover risks from tightening

Related News

  • North Korea's Dr Fauci? Health official emerges as face of Covid campaign
  • Shanghai detects new infections after five days of 'zero Covid'
  • North Korea hails 'good results' on Covid as fever cases pass 2 million
  • China relaxes some Covid test rules for US, other travellers
  • New York Times pauses return to office for workers

Features

Mohammad (Mejbah) Mejbahuddin, Former Senior Secretary, Economic Relations Division (ERD), Ministry of Finance, Government of Bangladesh. TBS Sketch

‘No project is being delayed too long at the moment’

14h | Panorama
Dr Shamsul Hoque, Professor, Civil Engineering, BUET. TBS Sketch

‘Planning commission only in the name, there are no planners’ 

14h | Panorama
Masrur Reaz. TBS Sketch

‘To ensure accountability, contract financing should be based on ‘performance based payments’

15h | Panorama
Professor Mustafizur Rahman. Illustration: TBS

Project delays and escalating costs are driven by frequent revisions and lack of good governance

18h | Panorama

More Videos from TBS

Ways to retain body fragrance

Ways to retain body fragrance

16h | Videos
Gazipur restaurant that serves 150 food items

Gazipur restaurant that serves 150 food items

19h | Videos
How to prepare for a job

How to prepare for a job

20h | Videos
Putin's strategies to face Nato

Putin's strategies to face Nato

1d | Videos

Most Read

1
Tk100 for bike, Tk2,400 for bus to cross Padma Bridge
Bangladesh

Tk100 for bike, Tk2,400 for bus to cross Padma Bridge

2
A packet of US five-dollar bills is inspected at the Bureau of Engraving and Printing in Washington March 26, 2015. REUTERS/Gary Cameron
Banking

Dollar hits Tk100 mark in open market

3
The story of Bangladesh becoming a major bicycle exporter
Industry

The story of Bangladesh becoming a major bicycle exporter

4
PK Halder: How a scamster rose from humble beginnings to a Tk11,000cr empire
Crime

PK Halder: How a scamster rose from humble beginnings to a Tk11,000cr empire

5
Representative Photo: Pixabay.
Bangladesh

Microplastics found in 5 local sugar brands

6
Mushfiq Mobarak. Photo: Noor-A-Alam
Panorama

Meet the Yale professor who anchors his research in Bangladesh and scales up interventions globally

The Business Standard
Top
  • Home
  • Entertainment
  • Sports
  • About Us
  • Bangladesh
  • International
  • Privacy Policy
  • Comment Policy
  • Contact Us
  • Economy
  • Sitemap
  • RSS

Contact Us

The Business Standard

Main Office -4/A, Eskaton Garden, Dhaka- 1000

Phone: +8801847 416158 - 59

Send Opinion articles to - oped.tbs@gmail.com

For advertisement- sales@tbsnews.net

Copyright © 2022 THE BUSINESS STANDARD All rights reserved. Technical Partner: RSI Lab